News

Cas5 dimer structure offers clues for CRISPR system engineering

Structural analysis of Cas5 from Moraxella bovoculi reveals that this protein functions equally well as a monomer or a dimer for RNA processing, but only monomers integrate into Cascade complexes. As CRISPR therapeutics move beyond single-protein systems, understanding Cas5 behaviour provides crucial design parameters for engineering next-generation type I-C platforms.

By: Gorm Palmgren - Dec. 15, 2025
News

While Cas5 is not a direct genome editor, it serves as a modular, engineerable component in multiprotein CRISPR systems that offer advantages over Cas9-based tools – including enhanced specificity through two-step target recognition and the capacity for large-scale DNA deletions relevant to antimicrobial and antiviral applications.

The research team demonstrated that MboCas5 forms stable dimers via salt bridges between the R72 and D167 residues; however, when they disrupted dimerisation with the R72W mutation, the resulting monomer retained full crRNA processing activity. This functional equivalence has important practical implications – researchers working with isolated Cas5 for in vitro RNA processing need not maintain specific oligomeric states. However, structural modelling revealed that dimeric Cas5 creates steric clashes with Cas8 in assembled Cascade complexes, explaining why only monomers incorporate into functional surveillance machinery.

The team also identified a flexible loop region undergoing substantial conformational rearrangement during Cascade assembly. For researchers engineering type I-C systems, modulating the R72-D167 interface could control Cas5 availability for complex formation, whilst the flexible loop represents a potential target for allosteric regulation or stability optimisation.

The study was led by Yong Jun Kang, Hyun Ji Ha and Hyun Ho Park at Chung-Ang University, Seoul, Republic of Korea. It was published in Scientific Reports on 15 December 2025.

To get more CRISPR Medicine News delivered to your inbox, sign up to the free weekly CMN Newsletter here.

Tags

HashtagArticleHashtagCMN BriefsHashtagNewsHashtagCRISPR ScreensHashtagCas9

CLINICAL TRIALS
Non-small Cell Lung Cancer, NSCLC, (NCT06097962)
Sponsors:
Base Therapeutics (Shanghai) Co., Ltd.
Indicator
IND Enabling
Phase I
Phase II
Phase III
Gastric Cancer and Colorectal Cancer, CRC, (NCT07166263)
Sponsors:
Base Therapeutics (Shanghai) Co., Ltd.  
Indicator
IND Enabling
Phase I
Phase II
Phase III
Relapsed or Refractory Acute Myeloid Leukemia, AML, (NCT06541444)
Sponsors:
Base Therapeutics (Shanghai) Co., Ltd.
Indicator
IND Enabling
Phase I
Phase II
Phase III
View all clinical trials
close
Search CRISPR Medicine